Foghorn Therapeutics is significantly reducing its workforce by nearly half. This decision comes after the company terminated its dr-g development partnership with Eli Lilly. The biotech firm is now focused on conserving its financial resources. This move indicates a shift towards a more defensive operational strategy. The partnership's dissolution is the primary driver for these substantial layoffs.
Cambridge, MA
https://www.barrons.com/articles/foghorn-therapeutics-stock-lilly-cancer-job-cuts-d43e6a0f